Telix Pharmaceuticals Limited (TLX)
| Market Cap | 2.34B |
| Revenue (ttm) | 803.79M |
| Net Income (ttm) | -7.13M |
| Shares Out | 338.78M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | 94.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,156 |
| Open | 7.00 |
| Previous Close | 7.25 |
| Day's Range | 6.85 - 7.04 |
| 52-Week Range | 6.28 - 20.00 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 21.13 (+200.14%) |
| Earnings Date | Feb 19, 2026 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $21.13, which is an increase of 200.14% from the latest price.
News
Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx
Telix Pharmaceuticals (TLX) maintains a "Buy" rating, driven by robust revenue growth and multiple late-stage oncology assets. TLX reported FY2025 revenue of $804 million, up 56% YoY, with Precision P...
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospita...
1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth
Telix's revenue grew by 56% in 2025. The Australian company develops drugs that can both detect and treat cancers.
Citigroup Raises Price Target on Telix Pharmaceuticals (TLX) to $22.50 | TLX Stock News
Citigroup Raises Price Target on Telix Pharmaceuticals (TLX) to $22.50 | TLX Stock News
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
Telix Pharmaceuticals Limited (TLX) Q4 2025 Earnings Call Transcript
Telix Pharmaceuticals Ltd (TLPPF) Full Year 2025 Earnings Call Highlights: Robust Revenue ...
Telix Pharmaceuticals Ltd (TLPPF) Full Year 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic R&D Investments
Full Year 2025 Telix Pharmaceuticals Ltd Earnings Call Transcript
Full Year 2025 Telix Pharmaceuticals Ltd Earnings Call Transcript
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended Decembe...
Telix Pharmaceuticals (TLX) Reports Earnings Miss, Revenue Growth
Telix Pharmaceuticals (TLX) Reports Earnings Miss, Revenue Growth
Telix Pharmaceuticals GAAP EPS of -$2.11 misses by $2.14, revenue of $803.8M misses by $22.79M
Telix Submits European Marketing Authorization Application For TLX101-Px
(RTTNews) - Telix Pharmaceuticals Limited (TLX) has submitted a marketing authorization application in Europe for TLX101-Px, its glioma imaging candidate. The submission covers major European markets....
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization ...
Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure
Telix Pharmaceuticals Limited (NASDAQ: TLX), a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue.
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action secur...
TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
FINAL DEADLINE ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
NEW YORK--(BUSINESS WIRE)---- $TLX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “...
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX
NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
TLX FINAL DEADLINE ALERT: Hagens Berman Alerts Telix Pharm. (TLX) Investors of Today's Lead Plaintiff Deadline in Securities Class Action
SAN FRANCISCO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to ...
TLX Deadline Tomorrow: Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action First Filed by the Firm – TLX
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28,...
Telix Pharmaceuticals Ltd. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights – TLX
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).
Deadline Soon: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming January 9, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsui...
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Partner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is i...
Bronstein, Gewirtz & Grossman LLC Urges Telix Pharmaceuticals Limited Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Telix Pharmaceuticals Limited investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 1/5/2026
DEADLINE TOMORROW: Berger Montague Advises Telix Pharmaceuticals Ltd. (TLX) Investors to Inquire About a Securities Fraud Class Action by January 9, 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd...